Type 2 Diabetes: Genetic Variants May Limit GLP-1 Drug Effectiveness

Top Summary

• What happened: A new study reveals that genetic variants can cause resistance to GLP-1 receptor agonists, common drugs for Type 2 diabetes.
• Why it matters: These variants, present in about 10% of the population, can reduce the effectiveness of drugs like Ozempic and Wegovy in lowering blood sugar.
• What changes for people: Identifying these variants early could help doctors prescribe more effective treatments faster, moving towards precision medicine.
• Who is affected: People with Type 2 diabetes who carry specific PAM enzyme genetic variants (p.S539W and p.D563G) may not respond as well to GLP-1 receptor agonists.

GLP-1 Resistance Unveiled

A recent study by Stanford Medicine and collaborators has identified genetic variants that may reduce the effectiveness of GLP-1 receptor agonists, commonly used to treat Type 2 diabetes.

These drugs, which include popular medications like Ozempic and Wegovy, might not work as well for people carrying these specific variants.

The research, published in Genome Medicine, highlights a phenomenon called GLP-1 resistance, where the hormone GLP-1 is less effective despite being present in higher levels.

The Role of PAM Enzyme

Researchers focused on genetic variants affecting the PAM enzyme, crucial for activating hormones, including GLP-1.

These variants, already known to be more common in people with diabetes, impair insulin release.

The study revealed that individuals with a specific PAM variant (p.S539W) had increased GLP-1 levels, but the hormone was less effective in lowering blood sugar.

"Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity. They were not reducing their blood sugar levels more quickly. More GLP-1 was needed to have the same biological effect, meaning they were resistant to GLP-1." - Anna Gloyn, DPhil, professor of pediatrics and of genetics

Confirming the Findings

The initial results were unexpected, leading the research team to spend years confirming the observation through various experiments.

Collaborations with researchers in Zurich using mouse models further validated the findings, showing similar signs of GLP-1 resistance.

Mice lacking the PAM gene exhibited elevated GLP-1 levels that did not effectively regulate blood sugar.

Impact on Diabetes Treatment

Researchers analyzed data from clinical trials of GLP-1 receptor agonists in people with diabetes to assess the therapeutic implications.

A meta-analysis of three trials, involving 1,119 participants, showed that individuals with PAM variants responded less effectively to the drugs.

Only about a quarter of non-carriers reached the target HbA1c level after six months, compared to 11.5% of participants with the p.S539W variant and 18.5% with the p.D563G variant.

A Complex Puzzle Remains

The underlying mechanism driving GLP-1 resistance remains unclear, described by researchers as a "million-dollar question."

Anna Gloyn likens it to insulin resistance, a complex phenomenon that scientists are still working to fully understand.

The study highlights the importance of personalized medicine in diabetes treatment, suggesting that genetic testing could help identify patients who are less likely to respond to GLP-1 receptor agonists.

What to Watch Next

Future research will focus on pinpointing the exact mechanisms behind GLP-1 resistance and exploring alternative drug formulations or medications that can overcome this resistance. Pharmaceutical companies are encouraged to analyze genetic data from their GLP-1 medication trials to identify further genetic variants affecting drug response.